Lidds AB — Investor Relations & Filings

Lidds AB is a pharmaceutical company specializing in drug delivery based on its proprietary NanoZolid® technology platform. This technology enables the local, controlled, and sustained release of drugs. A NanoZolid-formulated drug is administered as an injectable suspension that forms a solid, absorbable depot at the target site, releasing the active substance over a defined period. This approach is designed to increase local therapeutic effects while minimizing systemic side effects. The company is developing its own pipeline of products, with a primary focus on oncology. Key candidates in development include Liproca Depot for prostate cancer, Nanodotax (a formulation of the chemotherapy drug docetaxel), and Nanoimod (a TLR9 agonist). The versatile platform can be used to reformulate a wide range of drugs across various therapeutic areas.